|
1
|
Gazdar AF, Bunn PA and Minna JD:
Small-cell lung cancer: What we know, what we need to know and the
path forward. Nat Rev Cancer. 17:725–737. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Früh M, De Ruysscher D, Popat S, Crinò L,
Peters S and Felip E; ESMO Guidelines Working Group, : Small-cell
lung cancer (SCLC): ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 6 (24
Suppl):vi99–vi105. 2013.
|
|
3
|
Kalemkerian GP, Loo BW, Akerley W, Attia
A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A,
Downey RJ, et al: NCCN guidelines insights: Small cell lung cancer,
Version 2.2018. J Natl Compr Cancer Netw. 16:1171–1182. 2018.
View Article : Google Scholar
|
|
4
|
Owonikoko TK, Behera M, Chen Z, Bhimani C,
Curran WJ, Khuri FR and Ramalingam SS: A systematic analysis of
efficacy of second-line chemotherapy in sensitive and refractory
small-cell lung cancer. J Thorac Oncol. 7:866–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk
Y, Čučeviá B, Juhasz G, Thatcher N, Ross GA, Dane GC and Crofts T:
Phase III trial comparing supportive care alone with supportive
care with oral topotecan in patients with relapsed small-cell lung
cancer. J Clin Oncol. 24:5441–5447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eckardt JR, von Pawel J, Pujol JL, Papai
Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G and Ross G:
Phase III study of oral compared with intravenous topotecan as
second-line therapy in small-cell lung cancer. J Clin Oncol.
25:2086–2092. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Pawel J, Jotte R, Spigel DR, O'Brien
ME, Socinski MA, Mezger J, Steins M, Bosquee L, Bubis J, Nackaerts
K, et al: Randomized phase III trial of Amrubicin versus topotecan
as second-line treatment for patients with small-cell lung cancer.
J Clin Oncol. 32:4012–4019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Antonia SJ, López-Martin JA, Bendell J,
Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F,
et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent
small-cell lung cancer (CheckMate 032): A multicentre, open-label,
phase 1/2 trial. Lancet Oncol. 17:883–895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sato T, Teramukai S, Kondo H, Watanabe A,
Ebina M, Kishi K, Fujii Y, Mitsudomi T, Yoshimura M, Maniwa T, et
al: Impact and predictors of acute exacerbation of interstitial
lung diseases after pulmonary resection for lung cancer. J Thorac
Cardiovasc Surg. 147:1604–1611.e3. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raghu G, Nyberg F and Morgan G: The
epidemiology of interstitial lung disease and its association with
lung cancer. Br J Cancer. 2 Suppl 91:S3–S10. 2004. View Article : Google Scholar
|
|
11
|
Togashi Y, Masago K, Handa T, Tanizawa K,
Okuda C, Sakamori Y, Nagai H, Kim YH and Mishima M: Prognostic
significance of preexisting interstitial lung disease in Japanese
patients with small-cell lung cancer. Clin Lung Cancer. 13:304–311.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minegishi Y, Kuribayashi H, Kitamura K,
Mizutani H, Kosaihira S, Okano T, Seike M, Azuma A, Yoshimura A,
Kudoh S and Gemma A: The feasibility study of carboplatin plus
etoposide for advanced small cell lung cancer with idiopathic
interstitial pneumonias. J Thorac Oncol. 6:801–807. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshida T, Yoh K, Goto K, Niho S, Umemura
S, Ohmatsu H and Ohe Y: Safety and efficacy of platinum agents plus
etoposide for patients with small cell lung cancer with
interstitial lung disease. Anticancer Res. 33:1175–1180.
2013.PubMed/NCBI
|
|
14
|
Watanabe N, Taniguchi H, Kondoh Y, Kimura
T, Kataoka K, Nishiyama O, Kondo M and Hasegawa Y: Chemotherapy for
extensive-stage small-cell lung cancer with idiopathic pulmonary
fibrosis. Int J Clin Oncol. 19:260–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pelayo Alvarez M, Westeel V, Cortés-Jofré
M and Bonfill Cosp X: Chemotherapy versus best supportive care for
extensive small cell lung cancer. Cochrane Database Syst Rev.
27:CD0019902013.
|
|
16
|
Fujimoto D, Shimizu R, Kato R, Sato Y,
Kogo M, Ito J, Teraoka S, Otoshi T, Nagata K, Nakagawa A, et al:
Second-line chemotherapy for patients with small cell lung cancer
and interstitial lung disease. Anticancer Res. 35:6261–6266.
2015.PubMed/NCBI
|
|
17
|
Enomoto Y, Inui N, Imokawa S, Karayama M,
Hasegawa H, Ozawa Y, Matsui T, Yokomura K and Suda T: Safety of
topotecan monotherapy for relapsed small cell lung cancer patients
with pre-existing interstitial lung disease. Cancer Chemother
Pharmacol. 76:499–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miura Y, Saito Y, Atsumi K, Takeuchi S,
Miyanaga A, Mizutani H, Minegishi Y, Noro R, Seike M, Shinobu K, et
al: Interstitial lung disease associated with amrubicin
chemotherapy in patients with lung cancer: A single institutional
study. Jpn J Clin Oncol. 46:674–680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smit EF, Fokkema E, Biesma B, Groen HJ,
Snoek W and Postmus PE: A phase II study of paclitaxel in heavily
pretreated patients with small-cell lung cancer. Br J Cancer.
77:347–351. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamamoto N, Tsurutani J, Yoshimura N, Asai
G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y and Fukuoka
M: Phase II study of weekly paclitaxel for relapsed and refractory
small cell lung cancer. Anticancer Res. 26:777–781. 2006.PubMed/NCBI
|
|
21
|
Minegishi Y, Sudoh J, Kuribayasi H,
Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The
safety and efficacy of weekly paclitaxel in combination with
carboplatin for advanced non-small cell lung cancer with idiopathic
interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Travis WD, Costabel U, Hansell DM, King TE
Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU,
et al: An official American Thoracic Society/European Respiratory
Society statement: Update of the international multidisciplinary
classification of the idiopathic interstitial pneumonias. Am J
Respir Crit Care Med. 188:733–748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary
fibrosis: Evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Collard HR, Ryerson CJ, Corte TJ, Jenkins
G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM,
et al: Acute exacerbation of idiopathic pulmonary fibrosis an
international working group report. Am J Respir Crit Care Med.
194:265–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kenmotsu H, Naito T, Mori K, Ko R, Ono A,
Wakuda K, Imai H, Taira T, Murakami H, Endo M and Takahashi T:
Effect of platinum-based chemotherapy for non-small cell lung
cancer patients with interstitial lung disease. Cancer Chemother
Pharmacol. 75:521–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimizu R, Fujimoto D, Kato R, Otoshi T,
Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A,
et al: The safety and efficacy of paclitaxel and carboplatin with
or without bevacizumab for treating patients with advanced
nonsquamous non-small cell lung cancer with interstitial lung
disease. Cancer Chemother Pharmacol. 74:1159–1166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shukuya T, Ishiwata T, Hara M, Muraki K,
Shibayama R, Koyama R and Takahashi K: Carboplatin plus weekly
paclitaxel treatment in non-small cell lung cancer patients with
interstitial lung disease. Anticancer Res. 30:4357–4361.
2010.PubMed/NCBI
|
|
29
|
Kakiuchi S, Hanibuchi M, Tezuka T, Saijo
A, Otsuka K, Sakaguchi S, Toyoda Y, Goto H, Kawano H, Azuma M, et
al: Analysis of acute exacerbation of interstitial lung disease
associated with chemotherapy in patients with lung cancer: A
feasibility of S-1. Respir Investig. 55:145–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kenmotsu H, Naito T, Kimura M, Ono A,
Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T,
et al: The risk of cytotoxic chemotherapy-related exacerbation of
interstitial lung disease with lung cancer. J Thorac Oncol.
6:1242–1246. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ohshimo S, Ishikawa N, Horimasu Y, Hattori
N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J and
Costabel U: Baseline KL-6 predicts increased risk for acute
exacerbation of idiopathic pulmonary fibrosis. Respir Med.
108:1031–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Homma S, Sugino K and Sakamoto S: The
usefulness of a disease severity staging classification system for
IPF in Japan: 20 years of experience from empirical evidence to
randomized control trial enrollment. Respir Investig. 53:7–12.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH,
Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD,
et al: A multidimensional index and staging system for idiopathic
pulmonary fibrosis. Ann Intern Med. 156:684–691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kobayashi H, Naito T, Omae K, Omori S,
Nakashima K, Wakuda K, Ono A, Kenmotsu H, Murakami H, Endo M and
Takahashi T: ILD-NSCLC-GAP index scoring and staging system for
patients with non-small cell lung cancer and interstitial lung
disease. Lung Cancer. 121:48–53. 2018. View Article : Google Scholar : PubMed/NCBI
|
